KaydedilenlerDerginizi ekleyin

Dergiler / Journal of Basic and Clinical Health Sciences / 2022 / Cilt: 6 - Sayı: 1

Voriconazole-Induced Hepatotoxicity Concise up-to-date review

Özge AKÇAY
Mukaddes GÜMÜŞTEKİN
Sayfa
325–334
Yayın Tarihi
2022-01-27
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

This article reviews the epidemiology, mechanism, laboratory features of voriconazole-induced hepatotoxicity and current literature investigating the influence of voriconazole plasma concentration and CYP2C19 genetics on voriconazole-induced hepatotoxicity.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Voriconazole is a wide spectrum antifungal used primarily for invasive aspergillosis, an invasive mold infection occurs mostly in immunocompromised patients.
📊
Temel Bulgular & Veri:Even though reported incidence of hepatic adverse reactions during phase 2 and 3 clinical trials were less than 10%, observational studies in post marketing phase revealed much higher incidence reaching up to 69%.
💡
Sonuç & Katkı:This article reviews the epidemiology, mechanism, laboratory features of voriconazole-induced hepatotoxicity and current literature investigating the influence of voriconazole plasma concentration and CYP2C19 genetics on voriconazole-induced hepatotoxicity.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:voriconazole · hepatotoxicity · drug induced liver injury

Abstract

Voriconazole is a wide spectrum antifungal used primarily for invasive aspergillosis, an invasive mold infection occurs mostly in immunocompromised patients. Hepatotoxicity is the most common voriconazole-related adverse reaction that leads to treatment discontinuation. Even though reported incidence of hepatic adverse reactions during phase 2 and 3 clinical trials were less than 10%, observational studies in post marketing phase revealed much higher incidence reaching up to 69%. Therefore, the burden caused by hepatotoxicity and interruption of antifungal therapy put immunocompromised patients at serious risk. Currently, there is no biomarker in routine clinical use that can clearly predict susceptibility to voriconazole-induced hepatotoxicity. In effort to identify a predictor, plasma concentrations of voriconazole and cytochrome (CYP) 2C19 genotype/phenotype, which is responsible from substantial inter-individual changes in voriconazole pharmacokinetics, are the most studied subjects. Hepatotoxicity tends to occur at higher concentrations (>4 mg/L), but so far, no significant association has identified in this matter. Although CYP2C19 genotype is strongly associated with voriconazole plasma concentration, current data is insufficient to define a causal relationship between CYP2C19 genotype and voriconazole-induced hepatotoxicity. This article reviews the epidemiology, mechanism, laboratory features of voriconazole-induced hepatotoxicity and current literature investigating the influence of voriconazole plasma concentration and CYP2C19 genetics on voriconazole-induced hepatotoxicity.

🔖

Bu Makaleye Atıf Yap

AKÇAY, Ö., GÜMÜŞTEKİN, M. (2022). Voriconazole-Induced Hepatotoxicity Concise up-to-date review. Journal of Basic and Clinical Health Sciences, Cilt: 6 - Sayı: 1, 325–334. https://ajindex.com/articles/677066

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Andrade RJ, Chalasani N, Björnsson ES, et al. Drug-induced liver injury. Nat Rev Dis Prim 2019; 5(1): 1–22
  2. Larson A, Lindor K, Robson K. Drug-induced liver injury. UptoDate 2020 [Retrieved: 2020 Oct 15]. Available from:
  3. FDA. Center for Drug Evaluation and Research Center for Biologics Evaluation and Research. Drug-Induced Liver Injury: Premarketing Clinical Evaluation; 2009. Available from:
  4. Devarbhavi H, Dierkhising R, Kremers WK, Sandeep MS, Karanth D, Adarsh CK. Single-Center Experience With Drug-Induced Liver Injury From India: Causes, Outcome, Prognosis, and Predictors of Mortality. Am J Gastroenterol 2010; 105(11): 2396–404
  5. Zhou Y, Yang L, Liao Z, He X, Zhou Y, Guo H. Epidemiology of drug-induced liver injury in China: A systematic analysis of the Chinese literature including 21 789 patients. Eur J Gastroenterol Hepatol 2013; 25(7): 825–9
  6. Reuben A, Tillman H, Fontana RJ, et al. Outcomes in adults with acute liver failure between 1998 and 2013: An observational cohort study. Ann Intern Med 2016; 164(11): 724–32
  7. Suk KT, Kim DJ, Kim CH, et al. A prospective nationwide study of drug-induced liver injury in korea. Am J Gastroenterol 2012; 107(9): 1380–7
  8. Raschi E, Poluzzi E, Koci A, Caraceni P, De Ponti F. Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database. World J Hepatol 2014; 6(8): 601–12
  9. Pfizer. Vfend ® (voriconazole). Highlights of prescribing information. Available from:
  10. Cecil JA, Wenzel RP. Voriconazole: A broad-spectrum triazole for the treatment of invasive fungal infections. Expert Rev Hematol 2009; 2(3): 237-54
  11. Barbarino JM, Owusu Obeng A, Klein TE, Altman RB. PharmGKB summary: voriconazole pathway, pharmacokinetics. Pharmacogenet Genomics 2017; 27(5): 201–9
  12. FDA. VFEND ® I.V. (voriconazole) for Injection VFEND ® Tablets. Available from:
  13. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006; 46(2): 235–43
  14. Zonios D, Yamazaki